Enalkiren

Enalkiren

SCHEMBL123108

COc1ccc(C[C@H](NC(=O)CC(C)(C)N)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC2CCCCC2)[C@@H](O)[C@@H](O)CC(C)C)cc1

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
REN P00797 20/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Enalkiren SCHEMBL123107 0.87 REN (0.62) REN
SCHEMBL7334721 0.80 REN (0.52) REN
SCHEMBL13754442 0.79 REN (0.65) REN
SCHEMBL10381528 0.77 REN (0.63) REN
SCHEMBL7428433 0.76 REN (0.51) REN
SCHEMBL7335979 0.73 REN (0.53) REN
SCHEMBL8910133 0.73 REN (0.51) REN
SCHEMBL10381535 0.73 REN (0.63) REN
SCHEMBL9526952 0.72 REN (0.53) REN
SCHEMBL27692368 0.72 REN (0.80) REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206779-A1 ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF UNIVERSIDAD DE CHILE (CL) 2025-06-26 US claimed
WO-2025050228-A1 PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE OR A COMBINATION OF PEPTIDES AGONISTIC TO THE MAS, AT1 AND AT2 RECEPTORS PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) 2025-03-13 WO claimed
US-20250082608-A1 TREATMENT AND PREVENTION OF GLOMERULAR DISEASE SINGAPORE HEALTH SERVICES PTE LTD. (SG) 2025-03-13 US claimed
EP-4448096-A1 TREATMENT AND PREVENTION OF GLOMERULAR DISEASE Singapore Health Services Pte. Ltd. (SG) 2024-10-23 EP claimed
EP-4337675-A1 ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Universidad De Chile (CL) 2024-03-20 EP claimed
WO-2023111196-A1 TREATMENT AND PREVENTION OF GLOMERULAR DISEASE SINGAPORE HEALTH SERVICES PTE. LTD. (SG) 2023-06-22 WO claimed
WO-2022265697-A1 COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME Tiger Development, LLC (US) 2022-12-22 WO claimed
US-20220370360-A1 COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME ACCESS TO ADVANCED HEALTH INSTITUTE 2022-11-24 US claimed
WO-2022238734-A1 ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF UNIVERSIDAD DE CHILE (CL) 2022-11-17 WO claimed
US-20210401751-A1 COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME Tiger Development Inc. (US) 2021-12-30 US claimed
CN-1315853-A Bioenhanced formulations comprising eprosartan in oral dosage form SMITHKLINE BEECHAM CORP (US) 2001-10-03 CN claimed
US-5977159-A Medical use of an ace-inhibitor for treatment of dyspeptic symptoms ASTRA AKTIEBOLAG (SE) 1999-11-02 US claimed
CN-1207685-A Novel medical use of ACE-inhibitor for treatment of dyspeptic symptoms ASTRA AB (SE) 1999-02-10 CN claimed
EP-0876158-A1 NOVEL MEDICAL USE OF AN ACE-INHIBITOR FOR TREATMENT OF DYSPEPTIC SYMPTOMS Astra Aktiebolag (publ) (SE) 1998-11-11 EP claimed
WO-1997026014-A1 NOVEL MEDICAL USE OF AN ACE-INHIBITOR FOR TREATMENT OF DYSPEPTIC SYMPTOMS ASTRA AKTIEBOLAG (PUBL) (SE) 1997-07-24 WO claimed
EP-0674529-A1 LIPID PRODRUGS FOR ORAL ADMINISTRATION NeXstar Pharmaceuticals, Inc. (US) 1995-10-04 EP claimed
US-5411947-A converting drugs having suitable functional groups to 1-O-alkyl-, 1-O-acyl-, 1-S-acyl, and 1-S-alkyl-sn-glycero-3-phosphate derivatives; drugs such as AZT, cladribine, AICA-Riboside VESTAR, INC. (US) 1995-05-02 US claimed
WO-1994013324-A1 LIPID PRODRUGS FOR ORAL ADMINISTRATION VESTAR, INC. (US) 1994-06-23 WO claimed
US-5122514-A Administering renin inhibitor ABBOTT LABORATORIES (US) 1992-06-16 US claimed
WO-1991016031-A1 PSORIASIS TREATMENT ABBOTT LABORATORIES (US) 1991-10-31 WO claimed